Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

Proceedings of the National Academy of Sciences of the United States of America
Hannah AlphsRichard Roden

Abstract

Persistent infection with the high-risk subset of genitotropic human papillomavirus (HPV) genotypes is a necessary cause of cervical cancer. Given the global burden of cervical cancer, a low-cost, broadly protective vaccine is needed. RG-1 is a cross-neutralizing and protective monoclonal antibody that recognizes residues 17-36 of HPV16 minor capsid protein L2. Because this epitope is highly conserved in divergent HPV types, we determined whether vaccination with HPV16 L2 17-36 peptide is broadly protective. The peptide was administered to BALB/c mice three times at monthly intervals, either alone or in the context of a synthetic lipopeptide vaccine candidate (P25-P2C-HPV) produced by linkage of the HPV peptide with a broadly recognized T helper epitope (P25) and the Toll-like receptor-2 (TLR2) ligand dipalmitoyl-S-glyceryl cysteine (P2C). In contrast to vaccination with the L2 17-36 peptide or P25-P2C alone, a potent L2-specific antibody response was generated to the P25-P2C-HPV lipopeptide when delivered either s.c. or intranasally. Sera from mice vaccinated with the P25-P2C-HPV lipopeptide neutralized not only HPV16 pseudovirions but also other evolutionarily divergent oncogenic genital (HPV18, HPV45) and cutaneous (HPV5, BP...Continue Reading

References

Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R KirnbauerJ T Schiller
Aug 19, 1999·The Journal of Pathology·J M WalboomersN Muñoz
Nov 1, 1995·Cancer Control : Journal of the Moffitt Cancer Center·M S Hoffman, D Cavanagh
Mar 22, 2002·The Lancet Oncology·D M Parkin
Oct 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Weiguang ZengDavid C Jackson
Feb 7, 2003·The New England Journal of Medicine·Nubia MuñozUNKNOWN International Agency for Research on Cancer Multicenter Cervical Cancer Study Group
Dec 25, 2003·Journal of Virology·Christopher B BuckJohn T Schiller
Jun 9, 2004·Virology·Ethel-Michele de VilliersHarald zur Hausen
Oct 19, 2004·Proceedings of the National Academy of Sciences of the United States of America·David C JacksonLorena E Brown
Feb 15, 2005·Journal of Virology·Christopher B BuckJohn T Schiller
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Feb 6, 2007·Seminars in Immunology·Taro Kawai, Shizuo Akira
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Allan HildesheimUNKNOWN Costa Rican HPV Vaccine Trial Group
Oct 12, 2007·Journal of Virology·Ratish GambhiraRichard B S Roden

❮ Previous
Next ❯

Citations

Jan 27, 2009·Archives of Virology·Ramon PereiraEdward P Rybicki
Jan 22, 2010·Amino Acids·Weiguang ZengDavid C Jackson
May 8, 2009·Immunology and Cell Biology·Balasubramanyam KaranamRichard B S Roden
Feb 24, 2010·Immunology and Cell Biology·David PejoskiDavid C Jackson
Apr 8, 2009·Nature Medicine·Kirsten Dorans
May 28, 2009·Journal of the National Cancer Institute·Subhashini JaguRichard B S Roden
Jul 31, 2009·Journal of Virology·Christina SchellenbacherReinhard Kirnbauer
Nov 13, 2009·Journal of Virology·M Saveria Campo, Richard B S Roden
Mar 29, 2013·Journal of Virology·Subhashini JaguRichard B S Roden
Oct 29, 2010·Journal of Translational Medicine·Luciano Mariani, Aldo Venuti
Mar 26, 2010·Journal of Translational Medicine·Nicolas CombelasAntoine Touzé
Oct 29, 2009·Virology Journal·Ratish GambhiraRichard Roden
Dec 10, 2009·Future Microbiology·Patricia M Day, John T Schiller
Feb 2, 2012·Antiviral Therapy·Elizabeth D GerschRobert L Garcea
Jun 29, 2011·Therapeutic Delivery·Barbara MaT C Wu
May 3, 2013·Archives of Virology·Marieta McGrathEdward P Rybicki
Oct 7, 2009·Expert Review of Vaccines·Franco Maria BuonaguroLuigi Buonaguro
Feb 19, 2013·Expert Review of Vaccines·Joshua W Wang, Richard B S Roden
May 26, 2011·Expert Opinion on Biological Therapy·Franco M BuonaguroLuigi Buonaguro
Dec 15, 2015·Virology·Kristofer J ChristakosSamuel K Campos
Feb 25, 2014·Clinics in Dermatology·Lis Ribeiro-Müller, Martin Müller
Feb 4, 2010·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Ken LinT C Wu
Jun 12, 2013·The Journal of Investigative Dermatology·Christina SchellenbacherReinhard Kirnbauer
Oct 27, 2009·Archives of Medical Research·Lutz Gissmann
Feb 24, 2016·Expert Review of Vaccines·Rosie T JiangRichard B S Roden
Jun 13, 2009·International Journal of Cancer. Journal International Du Cancer·Silvia FranceschiCosette M Wheeler
Aug 9, 2013·Plant Biotechnology Journal·Catherine B PineoEdward P Rybicki

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.